Michelle Moh

Michelle Moh

Auto-generated profile, based on publicly available information

Michelle Moh

Department of Pathology, Cleveland Clinic (M.M.)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
MMMichelle Moh
Michelle Moh
APAndrii M.D. Puzyrenko
Andrii M.D. Puzyrenko
RSRebekah Summey
Rebekah Summey
JRJanet S. Rader
Janet S. Rader
GCGenaro Enrique Herrera Cano
Genaro Enrique Herrera Cano
EHElizabeth Hopp
Elizabeth Hopp
Adult granulosa cell tumors (AGCTs) are rare ovarian tumors with generally good prognosis after surgical resection; however, they do have recurrence potential. Therapeutic and management options for recurrences are currently limited, and the need for expanded adjuvant therapies is increasingly recognized. Anti-hormonal therapy is being explored as an option, which relies on the detection and assessment of hormone receptor expression (androgen, estrogen, and progesterone receptors) as a biomarker and therapeutic target. Our study identifies several clinicopathologic characteristics with significant associations for recurrence of AGCT, which were younger age, higher stage, and larger tumor size. Our study also demonstrates that androgen receptor (AR) expression may be utilized as a potential biomarker for hormonal therapy and that detection of AR expression in AGCT by immunohistochemistry (IHC) varies depending on the antibody clone used for testing. AR was detected in 95% of samples tested with antibodies derived from clone AR27. This detection rate is much higher than previously reported.